NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

• Status: RECRUITING
• Trial end date: 2030-09-01

Summary

The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.

• Phase: PHASE2

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborators: Lustgarten Foundation; NextCure, Inc.
• Treatments: Fluorouracil; Ipilimumab; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin